AccuMed and Biokit in joint venture:
This article was originally published in Clinica
Executive Summary
AccuMed International (US) and Biokit (Spain) have signed a joint venture agreement to develop a low-cost, automatic Kirby Bauer reader. Biokit will license software to AccuMed as part of a worldwide technology agreement. The deal "will result in the earlier development of our unique proprietary system for the $250 million market", says Peter Gombrich, CEO of AccuMed. Kirby Bauer systems test microbiology samples to identify the most suitable type and concentration of antibiotics. Terms of the deal were not disclosed.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.